70 Diagnostic Accuracy. Martin Kroll MD
|
|
- Maximilian Arnold
- 5 years ago
- Views:
Transcription
1 7 Diagnostic Accuracy Martin Kroll MD 2 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 6 Chicago, IL 663
2 7 Diagnostic Accuracy Pathologists and laboratory professionals can play a big role in cost containment and improving the quality of patient care by interpreting which new tests are useful for clinical use. One needs experience with tests for diagnostic accuracy (evidence-based medicine), such as ROC curves, odds ratios and relative risk to confidently interpret the clinical utility of new tests. The FDA requires such information with submissions. This session will provide the participant with the experience necessary to interpret the tests of diagnostic accuracy. Confidently interpret predictive value, ROC curves, odds ratios and relative risk. Describe the proper use of these tools. Explain the proper ways for these studies to be done. FACULTY: Martin Kroll MD Entire Pathology Team Chemistry Chemistry. CME/CMLE Credit Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Credit Designation: The ASCP designates this enduring material for a maximum of AMA PRA Category Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. ASCP continuing education activities are accepted by California, Florida, and many other states for relicensure of clinical laboratory personnel. ASCP designates these activities for the indicated number of Continuing Medical Laboratory Education (CMLE) credit hours. ASCP CMLE credit hours are acceptable to meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. All ASCP CMLE programs are conducted at intermediate to advanced levels of learning. Continuing medical education (CME) activities offered by ASCP are acceptable for the American Board of Pathology s Maintenance of Certification Program.
3 Diagnostic Accuracy Martin Kroll, MD Professor of Pathology and Laboratory Medicine Boston University School of Medicine Chief, Laboratory Medicine Boston Medical Center Disclosure Roche Abbott Course Objectives List reasons why diagnostic accuracy is important. Interpret Predictive value, ROC curves, odds ratio and relative risk. Describe the proper use of these tools. Evaluate the plan and quality of study designs
4 Diagnostic Accuracy The REASONS Why The Challenge of the Complex Patient Complex patients present with numerous risk factors (CHD, renal, metabolic) One-fourth US population has metabolic syndrome 8 million adults have cardiovascular disease Patients do better when Dx and Rx immediately and effectively for complications C Moriates, A Maisel. The Utility of Biomarkers in sorting out the complex patient. Amer J Med. 2; 23: Clinical Significance of Biomarkers for the Complex Patient Inexpensive tools that may help differentiate diseases in complex patients Both sensitive and specific: disease state Novel biomarkers Highly sensitive troponin Procalcitonin Neutralphil gelatinase lipocalin (N-GAL) C Moriates, A Maisel. The Utility of Biomarkers in sorting out the complex patient. Amer J Med. 2; 23:
5 Hypothetical Combination of BNP, N-GAL and Creatinine on Concentrati BNP N-GAL Determine the euvolemic state in Decompensated heart failure. creatinine Time C Moriates, A Maisel. The Utility of Biomarkers in sorting out the complex patient. Amer J Med. 2; 23: Important Biomarkers for CAD MI Risk LDL/HDL HgAc MPO CRP HCY Inflammation CRP CD4L OxLDL MCP- ST2 Fα Plaque Rupture MMPs CD4L MPO CRP HCY IL-6 Unstable Angina MPO D-dimer IMA FABP Myocard Ischemia MDA-LDL IMA FFA BNP Choline PIGF Myocardial Necrosis Myo CK-MB TnI/TnT BNP C Moriates, A Maisel. The Utility of Biomarkers in sorting out the complex patient. Amer J Med. 2; 23: Trend in Patient Care Patients are more complex: Obesity, CVD, DM, Metabolic Syndrome, Chronic renal disease Complex patients difficult to diagnose: need inexpensive tools Novel biomarkers further elucidate underlying pathologies with earlier detection C Moriates, A Maisel. The Utility of Biomarkers in sorting out the complex patient. Amer J Med. 2; 23:
6 Insulin, Proinsulin Risk Type 2 Diabetes Mellitus in Women Parameter Insulin, pmol/l, Q3 Insulin, pmol/l, Q4 Proinsulin, pmol/l Proinsulin, pmol/l Range Odds Ratio (95% C.I.) (.8-6.7) > (.8-8) 8) (.8-36) >=7. 6 (5.8-47) Pradhan. Am J Med. 23:4: Reference Range Concept F R A C T I O N Healthy 2 SD 2 SD Diseased TEST RESULT Clear separation Reference Range Reality F R A C T I O N Non-Diseased Indeterminant FN 2 SD 2 SD Diseased TEST RESULT FP 4
7 Definitions Sensitivity: Ability of a test to yield positive results for patients with the disease or condition Relates to true positives Specificity Ability of a test to yield negative results in the absence of the disease or condition Relates to true negatives Predictive Value of a Test P( T + / D) P( D) Bayes Theorem P( D / T + ) = P( T + ) PVP: likelihood that someone with a positive test will have the characteristic PVN: likelihood lih that t someone with a negative test will NOT have the characteristic What Physicians use Prevalence dependent Contingency Table Cond + Cond - Test PVP.62 Test neg Sensitivity Specificity PVN
8 The Problem of Prevalence: S&S =.9 Prevalence P(H)=.2 : PVP =.7; PVN =.97 P(H)=.5 : PVP =.3; PVN =.99 Usefulness depends on Prevalence. Cutoff crucial. F R A C T I O N Non-diseased Diseased cutoff TEST RESULT Designing the Basic Evaluation Define the Clinical Question Identify the role of the test(s) in making the decision. Select a Statistically Valid, Representative Study Sample Select, prospectively, a statistically valid sample that consists of representative subjects Establish the True Clinical State or Outcome of each Subject Test the Study Subjects Perform the test(s) without knowing the clinical classification of the subjects. Assess the Clinical Accuracy of the Test(s) Construct and analyze receiver operating characteristic (ROC) plots, calculate OR, RR, HR Define the Clinical Question Can the test discriminate between the condition and other disease states Example: troponin distinguish between MI and other chest pain causes Which test is best? Assume population of similar subjects Share disease characteristics, e.g., HF Age, gender, stage of disease 6
9 Select Representative Study Sample Choose a relevant sample of subjects; need a similar background Example: pancreatitis; both positive and negative groups should present with similar history and symptoms Disease Spectrum Stage of disease or condition Severity of disease Genetic background Body composition Multiple diseases (co-morbidity) Lifestyle Demographics Spectrum Effect Different condition substrata affects test performance estimators Condition of interest presented as binary More than binary manifestation Varying substrata alters ability of plot to adequately differentiate test abilities Alters Sensitivity and Specificity 7
10 Sample Size Dependent Prevalence Sensitivity Specificity Often Equal positive and negative Establish True Clinical State Gold Standard Biopsy Surgical or autopsy findings Imaging data Long-term clinical outcome Definitive test Independent Classification Determine clinical state independent of the test under investigation Avoid the circular argument Avoid similar il tests t Frequently violated 8
11 Running the Test Identical specimens For comparing two tests Same subject Obtained at the same time Assay when specimens are stable Analytical test conditions Accurate (trueness) Precision (reproducibility) Why Should One Learn About ROC Curves? Determine whether test is better than chance Find optimum cutoff Evaluate asymmetry between sensitivity and specificity Assessment of diagnostic accuracy Evaluate whether two tests for the same process have the same diagnostic accuracy Normals = Abnormals Normal Abnormal ROC Curve Numb ber PSA Value Sensitivity Specificity 9
12 Abnormals >> Normals Num mber Values Normal Cancer tivity Sensit Specificity Abnormals > Normals Co unt PSA Distributions PSA Normal Cancer Sens itivity PSA Specificity Table. Determinations of Assay X for Eight Patients. Assay X Patient D x
13 ) /8/2 Calculation for Values of X Assay Values Dis X > X > 2 X > 3 X > 4 X > 5 X > 6 2 FP 3 TP 3 FP 4 TP 5 TP 5 FP 6 TP TP FP TP TP FP TP FN TP TP FP TP FN FN TP FP TP FN FN FN TP FN FN FN FN TP FP 3 2 FN ROC Plot for Assay X.9.8 Sensitivity (true posit tives) No discrimination assay x Specificity (false positives) Dotted line intersects ROC curve where Sensitivity=Specificity,.75 ROC Plot for Assay X Ass ay X No discrimination Choosing the optimal CUTOFF. True positive rate (Sensitivity) False positive rate (-Specificity)
14 ) /8/2 Dotted line intersects ROC curve where Sensitivity=Specificity,.75 ROC Plot for Assay X Ass ay X No discrimination Choosing the optimal CUTOFF. True positive rate (Sensitivity) False positive rate (-Specificity) Choice of Sensitivity ROC Plot for Assay X Assay X No discrimination.9.8 True positive rate (Sensitivity y) False positive rate (-Specificity) Choice of Specificity ROC Plot for Assay X Assay X No discrimination.9.8 True positive rate (Se ensitivity) False positive rate (-Specificity) 2
15 Comparing Two Markers ROC curve for two diagnostic markers Sensitivit ty Marker A Marker B -Specificity AUC ROC Plot for Assay X As say X No discrimination True positive rate (Se ensitivity) B.5 C A AUC =.8 Is test useful if SE =.2? SE =.5? AUC z 5 =. SE False positive rate (-Specificity) Comparing Two Markers Hypothetical Marker Comparison AUC: A:.955 B:.89 Sensit tivity Are they significantly Different, if SE =.5 SE = z = AUC AUC 2 SE -Specificity Equivocal BNP NT-proBNP Test same samples from same patients Variance estimate includes correlation between samples 3
16 Uses of ROC Plots Determine whether test is better than chance Find optimum cutoff Evaluate asymmetry between sensitivity and specificity Assess diagnostic accuracy: AUC, C- statistic (additive effect) Compare two tests for same process: same or dissimilar diagnostic accuracies Clinical Evaluations Discrete Testing Two possibilities Tests Relative Risk Odds Ratio Comparison of means or distributions inadequate to assess diagnostic accuracy (t- test, non-parametric comparisons) Relative Risk of Disease (condition) Ratio of incidence of those with the positive test (T+) divided by those a negative test (T-) Calculated from a cohort where T+ and T- are identified first, and disease later Clinical Trials Originally used medication or toxic material 4
17 Relative Risk Many tests assign risk instead of discrimination between diseases Large studies Compare test positivity with risk of developing disease RR: prospective study Ratio disease positive test vs negative test Contingency Table: Relative Risk Cond + Cond - Risk Test T+.62 Test neg T-.37 Sensitivity Specificity Ratio Contingency Table: Relative Risk Cond + Cond - Risk Test + A B A+B T+ A/(A+B) Test neg C D C+D T- C/(C+D) A+C B+D A Sensitivity Specificity Ratio ( A+ B) RR= C A/(A+C) D/(B+D) ( C+ D) 5
18 Relative Risk: HOPE Study Microalbuminuria, >55 YO, h/o CVD or DM w risk factor 5 year interval: Albumin/creatinine ratio (urine) Mortality, + Mortality, - Risk Albuminuria, T+.7 Albuminuria, T Sensitivity Specificity Ratio CI Gerstein. JAMA 2; 286:42-6. Relative Risk of highest to lowest quartile CRP: 4.4 Interleukin 6: 2.2 LDL cholesterol: 2.4 Apoliprotein i B-: Q Q2 Q3 Q4 CRP and other inflammation markers in prediction of CDV in women. Ridker et al. N Engl J Med 2;342: Novel Risk Factors for Systemic Atherosclerosis (PAD) 95% C.I. Variable RR: Q3 RR: Q4 P value* LDL-C.8 (.9-3.8) 2.3 (.-4.7).3 HDL-C.6 (.3-.).5 (.2-.9).3 Apo-B 2. (.-4.3) 2.9 (.5-6.3) <. Lipoprotein(a).9 (.5-.8). (.6-2.2).6 Fibrinogen.4 (.7-2.9) 2.2 (.-4.7).2 CRP.7 (.7-3.4) 2.8 (.3-5.9). *Trend across quartiles. Ridker. JAMA 2:285:
19 Relative Risk Importance Large prospective studies Set policy and major practice patterns RR for cholesterol of 24 mg/dl is twice that for cholesterol at 2 mg/dl Expect values greater than., usually greater than.5 Odds Ratio Valuable in characterizing populations at risk Can identify when marker is not beneficial Sensitive to study stress on death or survival (RR insensitive to survival) Measures strength of association between marker and disease Judge using confidence limits Odds Ratio Equals RR only in rare diseases Not as reliable as relative risk Many more studies than with RR Positive over., expect > 3. Very useful, not as powerful as RR Uses much lower number of cases Case-control studies (less expensive than prospective studies) 7
20 Odds Ratio Interpretation When equal., no association When <., inverse association, less likely When >., direct association, more likely l Moderate association OR > 3. Pepe MS. Am J Epidemiol 24;59: Reasons for Odds Ratio Retrospective studies more common Use Odds ratio Fraction test positivity given disease divided id d by fraction test t negativity it in absence of disease Calculation of the Odds Ratio Cond + Cond - ODDS RATIO Test + A B Test neg C D A+C B+D Ratio A*D/B*C Sensitivity A/(A+C) Specificity D/(B+D) OR = Also by Logistic regression analysis A D B C 8
21 Odds Ratio: HOPE Study Microalbuminuria, >55 YO, h/o CVD or DM w risk factor 5 year interval: Albumin/creatinine ratio (urine) Mortality, + Mortality, - ODDS RATIO Albuminuria, A*D Albuminuria, Ratio B*C 392. Sensitivity Specificity Ratio RR.8 (.5-2.2) Gerstein. JAMA 2; 286:42-6. Insulin, Proinsulin Risk Type 2 Diabetes Mellitus in Women Parameter Insulin, pmol/l, Q3 Insulin, pmol/l, Q4 Proinsulin, pmol/l Proinsulin, pmol/l Range Odds Ratio (95% C.I.) (.8-6.7) > (.8-8) 8) (.8-36) >=7. 6 (5.8-47) Pradhan. Am J Med. 23:4: Assessment 54 Biomarkers for Biopsy- detectable Prostate Cancer Marker (serum) OR (P) AUC, % (P) PSA 2.74 (<.) 8.4 (<.) AFP.55 (.4) 57.5 (.2) Kallikrein 8.57 (.2) 57.3 (.2) MMP-2.93 (.65) 53.9 (.5) EGFR.65 (.34) 54.9 (.9) CEA.9 (.2) 54.9 (.9) Cancer Epid Biomarkers Prev 27;6:
22 Use of RR and OR For tests used to define risk: cholesterol, hs-crp, cancer, stroke, genomics Expect manufacturer to present information in package inserts and literature Should find published studies Conclusions Predictive value applies to patient Sensitivity and specificity are basic measures Remember for studies Same sample of subjects Same specimens to test Gold standard is critical Biomarkers must show independence ROC Curve Conclusions Prevalence independent Spectrum dependent Choose Cut-off AUC Test signficance Compare tests Evaluate improved information from test 2
23 Relative Risk and Odds Ratio Conclusions Define test usefulness Use Confidence interval to evaluate Prospective and case-controlled controlled studies Superior to t-testtest Perspective on Diagnostic Accuracy RR, OR and HR depicts association, not discrimination Need high values, best if > 3. Useful in eliminating i potential ti markers Confidence interval straddles. P >.5 Perspective on Diagnostic Accuracy RR and OR and HR can be statistically significant even with large overlap AUC (ROC) or c-statistic used for discrimination Affected by disease spectrum effect (bias) Other criteria Improvement shown change in c-statistic Reclassification 2
24 Change in c-statistic Use logistic regression Combine models Usual risk factors Typical biomarkers Varying combinations of the new markers Look for significant improvement in the c- statistic Examples change in c-statistic Hope study, addition of NT-proBNP raised AUC from.73 to.8 (signficant) Addition of genetic variant SNP 9p2 did not raise the AUC Studies using multiple genetic markers Raise the RR only about. As number genetic markers increase, incremental gain decreases TJ Wang. Circulation. 2;23: THANK YOU! 22
25 Contact Information Martin Kroll, MD Chief, Department of Laboratory Medicine Boston Medical Center 67 Albany Street, Room 735 Boston, MA Additional Slides Number of Samples TPF or FPF One half CI Width N 23
26 References Zweig M, Campbell G. Clin Chem 993;39:584. Mulherin SA, Miller WC. Spectrum bias. Ann Intern Med. 22;37: Hanley JA, McNeil BJ. The meaning and use of the area under a ROC curve. Radiology. 982;43: Hanley JA, McNeil BJ. A method of comparing the areas under ROC curves derived from the same cases. Radiology. 983;43: Zhou XH, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine, Wiley, NY,
2011 ASCP Annual Meeting
Diagnostic Accuracy Martin Kroll, MD Professor of Pathology and Laboratory Medicine Boston University School of Medicine Chief, Laboratory Medicine Boston Medical Center Disclosure Roche Abbott Course
More information78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP)
78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP) 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 1600 Chicago,
More information81 Stump the Stars 2011: Problem Cases in Hematopathology. Steven Kroft MD Russell Brynes MD LoAnn Peterson MD Eric Hsi MD Kaaren Reichard MD
81 Stump the Stars 2011: Problem Cases in Hematopathology Steven Kroft MD Russell Brynes MD LoAnn Peterson MD Eric Hsi MD Kaaren Reichard MD 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More information115 Endothelial Progenitor Cells: A Novel Laboratory-Based Biomarker of Vascular Health. Ishwarlal Jialal
115 Endothelial Progenitor Cells: A Novel Laboratory-Based Biomarker of Vascular Health Ishwarlal Jialal 211 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 16 Chicago,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationGenetic risk prediction for CHD: will we ever get there or are we already there?
Genetic risk prediction for CHD: will we ever get there or are we already there? Themistocles (Tim) Assimes, MD PhD Assistant Professor of Medicine Stanford University School of Medicine WHI Investigators
More informationVarious performance measures in Binary classification An Overview of ROC study
Various performance measures in Binary classification An Overview of ROC study Suresh Babu. Nellore Department of Statistics, S.V. University, Tirupati, India E-mail: sureshbabu.nellore@gmail.com Abstract
More information7/17/2013. Evaluation of Diagnostic Tests July 22, 2013 Introduction to Clinical Research: A Two week Intensive Course
Evaluation of Diagnostic Tests July 22, 2013 Introduction to Clinical Research: A Two week Intensive Course David W. Dowdy, MD, PhD Department of Epidemiology Johns Hopkins Bloomberg School of Public Health
More informationNet Reclassification Risk: a graph to clarify the potential prognostic utility of new markers
Net Reclassification Risk: a graph to clarify the potential prognostic utility of new markers Ewout Steyerberg Professor of Medical Decision Making Dept of Public Health, Erasmus MC Birmingham July, 2013
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationCritical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University
Critical reading of diagnostic imaging studies Constantine Gatsonis Center for Statistical Sciences Brown University Annual Meeting Lecture Goals 1. Review diagnostic imaging evaluation goals and endpoints.
More informationChapter 10. Screening for Disease
Chapter 10 Screening for Disease 1 Terminology Reliability agreement of ratings/diagnoses, reproducibility Inter-rater reliability agreement between two independent raters Intra-rater reliability agreement
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationSISCR Module 7 Part I: Introduction Basic Concepts for Binary Biomarkers (Classifiers) and Continuous Biomarkers
SISCR Module 7 Part I: Introduction Basic Concepts for Binary Biomarkers (Classifiers) and Continuous Biomarkers Kathleen Kerr, Ph.D. Associate Professor Department of Biostatistics University of Washington
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationSMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR
SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging
More informationBMI 541/699 Lecture 16
BMI 541/699 Lecture 16 Where we are: 1. Introduction and Experimental Design 2. Exploratory Data Analysis 3. Probability 4. T-based methods for continous variables 5. Proportions & contingency tables -
More informationSummary HTA. HTA-Report Summary
Summary HTA HTA-Report Summary Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events Schnell-Inderst
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationIntroduction to Epidemiology Screening for diseases
Faculty of Medicine Introduction to Community Medicine Course (31505201) Unit 4 Epidemiology Introduction to Epidemiology Screening for diseases By Hatim Jaber MD MPH JBCM PhD 15 +17-11- 2016 1 Introduction
More informationIntroduction to ROC analysis
Introduction to ROC analysis Andriy I. Bandos Department of Biostatistics University of Pittsburgh Acknowledgements Many thanks to Sam Wieand, Nancy Obuchowski, Brenda Kurland, and Todd Alonzo for previous
More informationΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος ΤΟΥΣΟΥΛΗΣ ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationKnowledge Discovery and Data Mining. Testing. Performance Measures. Notes. Lecture 15 - ROC, AUC & Lift. Tom Kelsey. Notes
Knowledge Discovery and Data Mining Lecture 15 - ROC, AUC & Lift Tom Kelsey School of Computer Science University of St Andrews http://tom.home.cs.st-andrews.ac.uk twk@st-andrews.ac.uk Tom Kelsey ID5059-17-AUC
More informationCRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
More informationStatistics, Probability and Diagnostic Medicine
Statistics, Probability and Diagnostic Medicine Jennifer Le-Rademacher, PhD Sponsored by the Clinical and Translational Science Institute (CTSI) and the Department of Population Health / Division of Biostatistics
More informationCochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Chapter 10 Analysing and Presenting Results Petra Macaskill, Constantine Gatsonis, Jonathan Deeks, Roger Harbord, Yemisi Takwoingi.
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationPredictive Models for Healthcare Analytics
Predictive Models for Healthcare Analytics A Case on Retrospective Clinical Study Mengling Mornin Feng mfeng@mit.edu mornin@gmail.com 1 Learning Objectives After the lecture, students should be able to:
More informationModule Overview. What is a Marker? Part 1 Overview
SISCR Module 7 Part I: Introduction Basic Concepts for Binary Classification Tools and Continuous Biomarkers Kathleen Kerr, Ph.D. Associate Professor Department of Biostatistics University of Washington
More informationScreening for Disease
Screening for Disease An Ounce of Prevention is Worth a Pound of Cure. Actually, an ounce of prevention is better than a pound of cure, but if prevention hasn t been effective, perhaps early identification
More information117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice. Gregory Flynn MD
117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice Gregory Flynn MD 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe,
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationBiomarkers in risk prediction of heart and kidney disease
Biomarkers in risk prediction of heart and kidney disease Winfried März Medizinische Universität Graz, Medizinische Klinik V Medizinische Fakultät Mannheim, Universität Heidelberg, Synlab Akademie, Mannheim
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationEvidence-Based Medicine: Diagnostic study
Evidence-Based Medicine: Diagnostic study What is Evidence-Based Medicine (EBM)? Expertise in integrating 1. Best research evidence 2. Clinical Circumstance 3. Patient values in clinical decisions Haynes,
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationThe recommended method for diagnosing sleep
reviews Measuring Agreement Between Diagnostic Devices* W. Ward Flemons, MD; and Michael R. Littner, MD, FCCP There is growing interest in using portable monitoring for investigating patients with suspected
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationAssessment of performance and decision curve analysis
Assessment of performance and decision curve analysis Ewout Steyerberg, Andrew Vickers Dept of Public Health, Erasmus MC, Rotterdam, the Netherlands Dept of Epidemiology and Biostatistics, Memorial Sloan-Kettering
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationLearning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III
Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDiscrimination and Reclassification in Statistics and Study Design AACC/ASN 30 th Beckman Conference
Discrimination and Reclassification in Statistics and Study Design AACC/ASN 30 th Beckman Conference Michael J. Pencina, PhD Duke Clinical Research Institute Duke University Department of Biostatistics
More informationInternational Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:
International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp. 072-078, September, 2018. www.premierpublishers.org, ISSN: 3102-9869 IJCCR Research Article Copeptin as a Novel Biomarker
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationEvidence Based Medicine Prof P Rheeder Clinical Epidemiology. Module 2: Applying EBM to Diagnosis
Evidence Based Medicine Prof P Rheeder Clinical Epidemiology Module 2: Applying EBM to Diagnosis Content 1. Phases of diagnostic research 2. Developing a new test for lung cancer 3. Thresholds 4. Critical
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationBiomarkers of myocardial infarction. Dr. Mamoun Ahram Cardiovascular system, 2013
Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013 References This lecture Hand-outs Acute Myocardial Infarction A rapid development of myocardial necrosis caused by prolonged
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationthe standard deviation (SD) is a measure of how much dispersion exists from the mean SD = square root (variance)
Normal distribution The normal distribution is also known as the Gaussian distribution or 'bell-shaped' distribution. It describes the spread of many biological and clinical measurements Properties of
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationOf the 1.5 million heart attacks
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke Paul M Ridker, MD, MPH Of the 1.5 million heart attacks and 600 000 strokes
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationLecture 14 Screening tests and result interpretation
Faculty of Medicine Epidemiology and Biostatistics الوبائيات واإلحصاء الحيوي (31505204) Lecture 14 Screening tests and result interpretation By Hatim Jaber MD MPH JBCM PhD 12-7-2017 1 1. Basic epidemiological
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More information2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.
Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationIt s hard to predict!
Statistical Methods for Prediction Steven Goodman, MD, PhD With thanks to: Ciprian M. Crainiceanu Associate Professor Department of Biostatistics JHSPH 1 It s hard to predict! People with no future: Marilyn
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationReview. Imagine the following table being obtained as a random. Decision Test Diseased Not Diseased Positive TP FP Negative FN TN
Outline 1. Review sensitivity and specificity 2. Define an ROC curve 3. Define AUC 4. Non-parametric tests for whether or not the test is informative 5. Introduce the binormal ROC model 6. Discuss non-parametric
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationLecture Outline Biost 517 Applied Biostatistics I. Statistical Goals of Studies Role of Statistical Inference
Lecture Outline Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Statistical Inference Role of Statistical Inference Hierarchy of Experimental
More informationSYSTEMATIC REVIEWS OF TEST ACCURACY STUDIES
Biomarker & Test Evaluation Program SYSTEMATIC REVIEWS OF TEST ACCURACY STUDIES Patrick MM Bossuyt Structure 1. Clinical Scenarios 2. Test Accuracy Studies 3. Systematic Reviews 4. Meta-Analysis 5.
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationBiomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease
Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationBiomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease
Biomarkers (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Policy Number: 2.04.65 Last Review: 1/2018 Origination: 1/2011 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More information